However, the possibility of osteoclast activation and osteoporosis after stroke is a potential problem with the use of rRANKL; RANK is expressed in osteoclast precursors and the stimulation of RANK signaling by the systemic injection of rRANKL could induce osteoporosis [5]. Here, TNFRSF11A is linked to Stroke.